Novare Capital Management LLC Grows Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Novare Capital Management LLC increased its stake in Thermo Fisher Scientific by 8.1% in Q2, now holding 24,496 shares valued at approximately $9.93 million.
• Insiders at Thermo Fisher Scientific sold a total of 30,066 shares worth nearly $14.2 million over the last 90 days, with the chief accounting officer reducing their ownership by 14.24%.
• Research analysts have set a consensus target price for Thermo Fisher Scientific at $589.10, with the stock currently rated as a "Moderate Buy."

Novare Capital Management LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 8.1% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 24,496 shares of the medical research company's stock after buying an additional 1,834 shares during the quarter. Novare Capital Management LLC's holdings in Thermo Fisher Scientific were worth $9,932,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of TMO. CBIZ Investment Advisory Services LLC lifted its stake in shares of Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after purchasing an additional 33 shares during the period. Anderson Financial Strategies LLC purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at approximately $30,000. Keystone Global Partners LLC purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at approximately $31,000. IMA Advisory Services Inc. purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at approximately $35,000. Finally, Smallwood Wealth Investment Management LLC purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at approximately $37,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Transactions at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock valued at $14,182,963 over the last 90 days. Company insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on TMO shares. Redburn Partners set a $580.00 target price on Thermo Fisher Scientific in a research note on Wednesday, October 8th. William Blair started coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They set an "outperform" rating for the company. HSBC reiterated a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Wells Fargo & Company lowered their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research note on Thursday, July 24th. Finally, Evercore ISI lifted their price objective on Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an "outperform" rating in a research note on Tuesday, October 7th. Fifteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and a consensus target price of $589.10.

Thermo Fisher Scientific Stock Up 0.4%

TMO stock opened at $539.05 on Friday. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The business has a fifty day moving average price of $495.74 and a 200-day moving average price of $449.41. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The stock has a market capitalization of $203.55 billion, a P/E ratio of 31.18, a P/E/G ratio of 2.91 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter in the previous year, the business earned $5.37 earnings per share. The company's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.